The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| MESO | +82.09% | -23.37% | -5.18% | +111% |
| S&P | +14.5% | +93.32% | +14.09% | +427% |
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target the cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Itescu Silviu on June 8, 2004 and is headquartered in Melbourne, Australia.
The company's shares continued to tumble after it received a Complete Response Letter last week from the FDA.
The company received a Complete Response Letter from the FDA regarding its prospective graft-versus-host disease therapy.
Currently no data to display
Currently no data to display.
Currently no data to display.
| Metric | YoY Change |
|---|
MESO earnings call for the period ending December 31, 2021.
MESO earnings call for the period ending June 30, 2021.
MESO earnings call for the period ending March 31, 2021.
MESO earnings call for the period ending September 30, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
